Synthetic Biology Market to Reach US$ 67.47 Billion by 2033 at 20.9% CAGR; North America Leads with 42% Share | Key Players Thermo Fisher Scientific, Illumina, Merck KGaA

The Synthetic Biology Market was valued at US$ 12.37 billion in 2024, up from US$ 10.38 billion in 2023, and is expected to reach US$ 67.47 billion by 2033, growing at a CAGR of 20.9% during the forecast period 2025-2033.

Market growth is driven by the expanding application of synthetic biology across healthcare, agriculture, industrial biotechnology, and environmental sustainability. Advances in gene editing, DNA synthesis, metabolic engineering, and bioinformatics are enabling the design and manufacture of novel biological systems for drug development, vaccines, bio-based chemicals, and sustainable materials. Increasing investment from governments and private organizations, along with rising adoption of automation, AI-driven design tools, and high-throughput screening, is accelerating innovation and commercialization. These factors collectively position synthetic biology as a transformative technology with strong long-term growth potential.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/synthetic-biology-market?sai-v
Synthetic Biology Market is the global market for technologies and applications that design, engineer, and modify biological systems and organisms for use in healthcare, agriculture, industrial biotechnology, and energy sectors.

Key Developments
✅ January 2026: In the United States, biotechnology companies accelerated adoption of synthetic biology platforms such as gene synthesis, CRISPR-based genome engineering, and automated biofoundries to advance applications in therapeutics, industrial enzymes, and sustainable chemicals.

✅ January 2026: In Europe, increased funding for bio-based manufacturing and climate-focused innovation supported expanded use of synthetic biology in biofuels, specialty chemicals, and sustainable materials development.

✅ January 2026: In Japan, research institutions and industrial players strengthened synthetic biology programs focused on precision fermentation, biomanufacturing efficiency, and next-generation biomaterials.

✅ December 2025: In the United States, growing collaboration between pharmaceutical companies and synthetic biology startups accelerated the design and optimization of novel biologics and cell-based therapies.

✅ December 2025: In Asia-Pacific, expanding government-backed biotechnology initiatives supported the development of synthetic biology applications in agriculture, food technology, and environmental remediation.

✅ November 2025: In Europe, integration of AI-driven design tools with synthetic biology workflows improved strain engineering efficiency and reduced development timelines.

Mergers & Acquisitions
✅ January 2026: In the United States, a life sciences and industrial biotechnology company acquired a synthetic biology platform provider to strengthen capabilities in automated strain engineering and bio-based product development.

✅ December 2025: In Europe, a specialty chemicals group completed the acquisition of a synthetic biology startup focused on precision fermentation technologies.

✅ December 2025: In Japan, a biotechnology company expanded its synthetic biology portfolio through the acquisition of a gene synthesis and DNA design technology firm.

✅ October 2025: In Asia-Pacific, a biomanufacturing services company acquired a regional synthetic biology startup to enhance scale-up and commercialization capabilities.

Key Players
Illumina | Thermo Fisher Scientific | Merck KGaA | Bota Biosciences | Codexis | Twist Bioscience | Creative Biogene | Eurofins Genomics | Others

Key Highlights
Thermo Fisher Scientific holds 24.3% share, driven by its end-to-end synthetic biology and genomics workflow solutions, strong reagent portfolio, and global laboratory customer base.

Illumina holds 21.1% share, supported by its dominance in next-generation sequencing platforms essential for synthetic biology research and large-scale genomic engineering.

Merck KGaA holds 16.8% share, leveraging its extensive life science reagents, genome editing tools, and strong penetration in academic and industrial research.

Twist Bioscience holds 11.6% share, driven by its high-throughput DNA synthesis capabilities, cost-efficient gene synthesis, and strong adoption in synthetic biology applications.

Codexis holds 9.4% share, supported by its expertise in protein engineering, enzyme optimization, and biocatalysis solutions for industrial biotechnology.

Eurofins Genomics holds 7.2% share, focused on gene synthesis, sequencing services, and strong presence across Europe and North America.

Creative Biogene holds 5.4% share, driven by customized synthetic biology services, genetic engineering solutions, and CRO-based research support.

Bota Biosciences holds 3.8% share, leveraging AI-driven metabolic engineering platforms and growing adoption in sustainable chemical and materials development.

Others account for 0.4% share, comprising emerging startups and niche providers offering specialized synthetic biology tools and services.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=synthetic-biology-market?sai-v

Market Drivers
- Rapid advancements in genetic engineering, CRISPR technologies, and DNA synthesis enabling novel design and modification of biological systems.

- Growing demand for sustainable bioproduction of chemicals, fuels, food ingredients, and materials via engineered organisms.

- Increasing investments in biofoundries, synthetic biology startups, and government funding for biotechnology innovation.

- Rising application of synthetic biology in healthcare, including biologics, cell and gene therapies, and personalized medicine.

- Expansion of data-driven biology with AI, automation, and high-throughput workflows accelerating design-build-test cycles.

Industry Developments
- Launch of integrated synthetic biology platforms combining design tools, automation, and analytics for rapid strain engineering.

- Strategic partnerships between academic institutions, biotech companies, and industrial players to scale applications in biomanufacturing and therapeutics.

- Development of advanced bioproduction processes for biofuels, bioplastics, and specialty chemicals using engineered microbes.

- Expansion of DNA synthesis capacity and drop-in biological parts libraries to support rapid prototyping.

- Increasing focus on regulatory frameworks, bioethics, and governance to ensure safe and responsible use of synthetic biology technologies.

Regional Insights
North America - 42% share: "Driven by strong biotech research ecosystem, high venture and government funding, and early adoption of synthetic biology tools."

Europe - 27% share: "Supported by collaborative research networks, strategic bioeconomy initiatives, and growing industrial biotech applications."

Asia Pacific - 24% share: "Fueled by expanding life sciences R&D, rising investments in industrial biotech, and government policies promoting innovation."

Latin America - 5% share: "Driven by improving biotech infrastructure, agricultural bioengineering projects, and emerging synthetic biology initiatives."

Middle East & Africa - 2% share: "Supported by nascent biotech programs, research collaborations, and expanding interest in bioindustrial applications."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/synthetic-biology-market?sai-v

Key Segments

By Product Type
Oligonucleotides and synthetic DNA hold a major share, driven by their extensive use in gene synthesis, diagnostics, and therapeutic research. Enzymes represent a significant segment, supported by their critical role in genome editing, amplification, and molecular assembly processes. Cloning technology kits are widely adopted due to their ease of use and reliability in genetic manipulation workflows. Synthetic cells are an emerging segment, gaining attention for advanced research and bioengineering applications. Xeno-nucleic acids are witnessing growing interest as researchers explore alternatives to natural DNA and RNA. Chassis organisms and other products continue to support large-scale synthetic biology development and commercialization.

By Technology
Genome engineering dominates the market, driven by rapid adoption of gene editing tools such as CRISPR and related technologies. Sequencing plays a vital role by enabling accurate design, validation, and analysis of synthetic constructs. Bioinformatics is experiencing strong growth due to the need for data-driven design, modeling, and optimization of biological systems. Cloning technologies remain essential for gene assembly and expression. Nanotechnology and other technologies are expanding steadily, supporting innovation in delivery systems and nanoscale bioengineering.

By Application
Medical applications represent the largest segment, driven by rising demand for synthetic biology in therapeutics, vaccines, diagnostics, and personalized medicine. Industrial applications are growing steadily, supported by the use of engineered organisms in biofuels, chemicals, and sustainable manufacturing. Food and animal health applications are expanding due to advancements in alternative proteins, feed additives, and veterinary solutions. Agricultural applications are gaining momentum through genetically engineered crops and bio-based inputs. Environmental applications and other uses are emerging, supported by bioremediation, waste treatment, and sustainability initiatives.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.